DUX4 and Facioscapulohumeral dystrophy: Here we show that apabetalone downregulates expression of DUX4 target genes, improves composite biomarkers of DUX4 activity, counters downregulation of some DUX4-associated KEGG pathways, and improves some MSigDB Hallmarks linked to FSHD pathology.